W.R. Gerritsen

444 total citations
20 papers, 369 citations indexed

About

W.R. Gerritsen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, W.R. Gerritsen has authored 20 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Immunology. Recurrent topics in W.R. Gerritsen's work include Prostate Cancer Treatment and Research (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). W.R. Gerritsen is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). W.R. Gerritsen collaborates with scholars based in United States, Netherlands and United Kingdom. W.R. Gerritsen's co-authors include RJ O’Reilly, Hugo Castro‐Malaspina, NA Kernan, JH Bourhis, SC Jhanwar, John F. Donohue, J. G. J. Bauman, Hidde J. Haisma, Dinja Oosterhoff and Marlies de Graaf and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

W.R. Gerritsen

20 papers receiving 355 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W.R. Gerritsen United States 9 144 125 116 107 78 20 369
Nicholas A. Zorko United States 11 78 0.5× 165 1.3× 104 0.9× 176 1.6× 95 1.2× 31 470
Rouzbeh Chegeni Canada 9 220 1.5× 107 0.9× 180 1.6× 74 0.7× 16 0.2× 24 422
María Vela Spain 12 57 0.4× 319 2.6× 118 1.0× 295 2.8× 40 0.5× 24 488
JK Brennan United States 8 173 1.2× 60 0.5× 122 1.1× 147 1.4× 34 0.4× 16 388
Fumimaro Takaku Japan 8 128 0.9× 142 1.1× 107 0.9× 194 1.8× 23 0.3× 11 442
A. Keith Stewart United States 10 134 0.9× 132 1.1× 205 1.8× 60 0.6× 23 0.3× 17 419
Anna Wolska Poland 13 75 0.5× 148 1.2× 166 1.4× 205 1.9× 27 0.3× 29 512
Larry Herrera United States 10 85 0.6× 167 1.3× 104 0.9× 125 1.2× 12 0.2× 13 415
Kazuko Tsuneoka Japan 11 59 0.4× 93 0.7× 132 1.1× 176 1.6× 40 0.5× 27 389
B D Chen United States 9 54 0.4× 64 0.5× 103 0.9× 178 1.7× 51 0.7× 9 370

Countries citing papers authored by W.R. Gerritsen

Since Specialization
Citations

This map shows the geographic impact of W.R. Gerritsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.R. Gerritsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.R. Gerritsen more than expected).

Fields of papers citing papers by W.R. Gerritsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.R. Gerritsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.R. Gerritsen. The network helps show where W.R. Gerritsen may publish in the future.

Co-authorship network of co-authors of W.R. Gerritsen

This figure shows the co-authorship network connecting the top 25 collaborators of W.R. Gerritsen. A scholar is included among the top collaborators of W.R. Gerritsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.R. Gerritsen. W.R. Gerritsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Omlin, Aurelius, Julie N. Graff, Christopher Hoimes, et al.. (2020). 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update. Annals of Oncology. 31. S514–S515. 4 indexed citations
2.
3.
Vincentis, Giuseppe De, W.R. Gerritsen, Jürgen E. Gschwend, et al.. (2019). Advances in targeted alpha therapy for prostate cancer. Annals of Oncology. 30(11). 1728–1739. 41 indexed citations
4.
5.
6.
7.
8.
Gerritsen, W.R., Alfons J. van den Eertwegh, Tanja D. de Gruijl, et al.. (2008). Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). Journal of Clinical Oncology. 26(15_suppl). 5146–5146. 34 indexed citations
9.
Idema, Sander, A.A. Geldof, Clemens M.F. Dirven, et al.. (2007). Evaluation of Adenoviral Oncolytic Effect on Glioma Spheroids by <SUP>18</SUP>F-DG Positron-Emission Tomography. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 16(10). 471–477. 5 indexed citations
10.
Gerritsen, W.R., Alfons J. van den Eertwegh, Tanja D. de Gruijl, et al.. (2007). Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC). Journal of Clinical Oncology. 25(18_suppl). 5120–5120. 15 indexed citations
11.
Oosterhoff, Dinja, Marlies de Graaf, Giuseppe Giaccone, et al.. (2005). Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11. British Journal of Cancer. 92(5). 882–887. 22 indexed citations
12.
Palmer, Daniel H., Vivien Mautner, Diana Hull, et al.. (2005). Virus-directed enzyme prodrug therapy (VDEPT): A clinical trial of adenovirus-delivered nitroreductase (NTR) in combination with CB1954 in patients with primary or secondary liver cancer. Journal of Clinical Oncology. 23(16_suppl). 3157–3157. 3 indexed citations
13.
Graaf, Marlies de, Epie Boven, Dinja Oosterhoff, et al.. (2002). A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. British Journal of Cancer. 86(5). 811–818. 27 indexed citations
14.
Oosterhoff, Dinja, Herbert M. Pinedo, Marlies de Graaf, et al.. (2002). Secreted and tumour targeted human carboxylesterase for activation of irinotecan. British Journal of Cancer. 87(6). 659–664. 36 indexed citations
15.
Haisma, Hidde J., et al.. (2000). Targeted enzymes for molecular chemotherapy. Cancer Gene Therapy. 7(8). 1208–1208. 2 indexed citations
16.
17.
18.
Gerritsen, W.R., et al.. (1994). Detection of chimerism in subpopulations of cells by fluorescence in situ hybridization and immunofluorescent staining of cell surface antigens.. PubMed. 13(4). 441–7. 11 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicholas A. Zorko Breakdown of academic impact, for papers by Rouzbeh Chegeni Breakdown of academic impact, for papers by María Vela Breakdown of academic impact, for papers by JK Brennan Breakdown of academic impact, for papers by Fumimaro Takaku Breakdown of academic impact, for papers by A. Keith Stewart Breakdown of academic impact, for papers by Anna Wolska Breakdown of academic impact, for papers by Larry Herrera Breakdown of academic impact, for papers by Kazuko Tsuneoka Breakdown of academic impact, for papers by B D Chen
Rankless by CCL
2026